Simple Test Predicts Childhood Cancer Relapse
|
By LabMedica International staff writers Posted on 26 May 2016 |

Image: The IncuCyte zoom continuous live-cell imaging and analysis system (Photo courtesy of Essen Biosciences).
High-risk neuroblastoma, which occurs mostly in children under five, is treated with surgery and chemotherapy, and neuroblastomas currently rated low risk are just removed or left untreated while doctors 'wait and see', but a fraction of low risk tumors recur and ultimately kill.
A cheap simple test could accurately predict the recurrence of a childhood cancer, as a protein marker has been pinpointed which when absent, shows neuroblastoma is almost certain to recur. It means children with low-risk neuroblastoma, who do not have the biomarker, can be reclassified as at high risk of relapse and have chemotherapy earlier.
Scientists at Brunel University London (UK) and their colleagues collected a retrospective series of primary tumors from neuroblastoma (NB) patients. Formalin-fixed, paraffin-embedded tissue sections from NB tumors were studied. Each tumor area tested contained malignant cells, assessed by histological examination. Quantification of immunofluorescence- or DAB-positive tumor cells was performed on serial tumor tissue sections. Tumor cells were distinguished in the samples using NB-specific marker, the homophilic binding glycoprotein neural cell adhesion molecule (NCAM, CD56).
The scientists carried out cell proliferation assays using IncuCyte live-cell imaging system (Essen Biosciences, Ann Arbor, MI, USA); immunostaining of cultured cells; Western blotting; angiogenesis assays where the images were captured using JuLI smart fluorescent cell analyzer (Baker Ruskinn, Sanford, ME; USA). The investigators used several other methodologies to identify the Promyelocytic Leukaemia protein-1(PML-1) and gene expression was assessed using chip microarrays.
PML was detected in the developing and adult sympathetic nervous system, whereas it was not expressed or low in metastatic neuroblastoma tumors. Reduced PML expression in patients with low-risk cancers, i.e. localized and negative for the V-Myc Avian Myelocytomatosis Viral Oncogene Neuroblastoma Derived Homolog (MYCN) protooncogene was strongly associated with tumor recurrence. PML-I, but not PML-IV, isoform suppresses angiogenesis via upregulation of thrombospondin-2 (TSP-2), a key inhibitor of angiogenesis. Finally, PML-I and TSP-2 expression inversely correlates with tumor angiogenesis and recurrence in localized neuroblastomas.
Paolo Salomoni, PhD, a professor and senior author of the study said, “We have found the absence of PML a very precise marker of tumor recurrence. In the low risk tumors, the absence of PML will be a very useful marker. What we can now say is that even some tumors classified as low risk, that would have previously gone untreated, if they show no expression of PML, they ought now to be classified as high risk.” The study was published on April 13, 2016, in the journal Clinical Cancer Research.
Related Links:
Brunel University London
Essen Biosciences
Baker Ruskinn
A cheap simple test could accurately predict the recurrence of a childhood cancer, as a protein marker has been pinpointed which when absent, shows neuroblastoma is almost certain to recur. It means children with low-risk neuroblastoma, who do not have the biomarker, can be reclassified as at high risk of relapse and have chemotherapy earlier.
Scientists at Brunel University London (UK) and their colleagues collected a retrospective series of primary tumors from neuroblastoma (NB) patients. Formalin-fixed, paraffin-embedded tissue sections from NB tumors were studied. Each tumor area tested contained malignant cells, assessed by histological examination. Quantification of immunofluorescence- or DAB-positive tumor cells was performed on serial tumor tissue sections. Tumor cells were distinguished in the samples using NB-specific marker, the homophilic binding glycoprotein neural cell adhesion molecule (NCAM, CD56).
The scientists carried out cell proliferation assays using IncuCyte live-cell imaging system (Essen Biosciences, Ann Arbor, MI, USA); immunostaining of cultured cells; Western blotting; angiogenesis assays where the images were captured using JuLI smart fluorescent cell analyzer (Baker Ruskinn, Sanford, ME; USA). The investigators used several other methodologies to identify the Promyelocytic Leukaemia protein-1(PML-1) and gene expression was assessed using chip microarrays.
PML was detected in the developing and adult sympathetic nervous system, whereas it was not expressed or low in metastatic neuroblastoma tumors. Reduced PML expression in patients with low-risk cancers, i.e. localized and negative for the V-Myc Avian Myelocytomatosis Viral Oncogene Neuroblastoma Derived Homolog (MYCN) protooncogene was strongly associated with tumor recurrence. PML-I, but not PML-IV, isoform suppresses angiogenesis via upregulation of thrombospondin-2 (TSP-2), a key inhibitor of angiogenesis. Finally, PML-I and TSP-2 expression inversely correlates with tumor angiogenesis and recurrence in localized neuroblastomas.
Paolo Salomoni, PhD, a professor and senior author of the study said, “We have found the absence of PML a very precise marker of tumor recurrence. In the low risk tumors, the absence of PML will be a very useful marker. What we can now say is that even some tumors classified as low risk, that would have previously gone untreated, if they show no expression of PML, they ought now to be classified as high risk.” The study was published on April 13, 2016, in the journal Clinical Cancer Research.
Related Links:
Brunel University London
Essen Biosciences
Baker Ruskinn
Latest Molecular Diagnostics News
- Multimodal AI Blood Test Aims to Improve Early Lung Cancer Screening
- FDA Clears Three-Virus Respiratory Panel for Anterior Nasal Swabs
- Whole Transcriptome Analysis Expands Understanding of Cancer Gene Fusions
- Fapon Showcases AI-Engineered Enzymes and RNA Workflows at AMP 2026
- AMP 2026 Underscores Molecular Testing’s Role in Precision Medicine for Women’s Health
- Target-Amplification-Free CRISPR Platform Demonstrates Molecular Detection in Under 10 Minutes
- Epigenetic Blood Test Detects Early Breast Cancer and Predicts Recurrence Risk
- Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment
- Lung Cancer Atlas Reveals Cellular Patterns Associated With Patient Prognosis
- AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026
- AMP 2026 Highlights Advances in Molecular Testing for Pediatric Diseases
- Liquid Biopsy Expands Insights Into Treatment Response and Tumor Alterations
- Blood Test Identifies Candidates for Targeted Radiotherapy in Advanced Prostate Cancer
- Genomic Studies Investigate Treatment Response and Inherited Risk in Sarcoma
- Liquid Biopsy Captures Gene Activity Patterns in Small-Cell Lung Cancer
- Genomic Sequencing Identifies Actionable Findings to Guide Rare Disease Management
Channels
Clinical Chemistry
view channel
Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research
Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more
Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk
Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read moreMolecular Diagnostics
view channel
Multimodal AI Blood Test Aims to Improve Early Lung Cancer Screening
Lung cancer screening can detect stage 1 disease, but false-positive findings, repeated follow-up, and radiation exposure remain important concerns. Current NHS screening is limited to current and former... Read more
FDA Clears Three-Virus Respiratory Panel for Anterior Nasal Swabs
Influenza and respiratory syncytial virus (RSV) often circulate during the same season and cause overlapping symptoms, making accurate differentiation important for clinical management. Seasonal testing... Read moreHematology
view channel
Werfen Gains FDA Clearance for ROTEM sigma Cartridge Use in Trauma
Traumatic injuries account for approximately 10% of deaths worldwide, with uncontrolled bleeding remaining a leading cause of potentially preventable trauma-related death. Trauma-induced coagulopathy further... Read more
Serial Blood Samples Reveal Leukemia’s Evolution Decades Before Diagnosis
Acute myeloid leukemia (AML) is an aggressive blood cancer affecting approximately 2,700 people in the U.K. annually, with only about one in six patients surviving five years after diagnosis.... Read moreImmunology
view channel
Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice
Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more
Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis
Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more
Antibody Testing Informs Melioidosis Diagnosis and Surveillance in Emerging Regions
Melioidosis is a serious and sometimes fatal infection caused by the soil- and water-dwelling bacterium Burkholderia pseudomallei. People and animals can contract the disease through exposure to contaminated... Read moreMicrobiology
view channel
New WHO Tools Address Gaps in Antimicrobial Resistance Testing
Antimicrobial resistance (AMR) is a growing global health threat, making infections increasingly difficult to diagnose and treat as they become resistant to standard antibiotics. Its spread is driven partly... Read more
Complete Malaria Genomes Could Improve Species Identification and Surveillance
Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read moreTechnology
view channel
New qPCR Master Mixes Offer Broad Compatibility for Routine Research
Quantitative PCR (qPCR) workflows require consistent reagent performance across instruments and assay formats. Laboratories must also manage costs without changing established protocols.... Read more
Multi-Agent AI Framework Supports Laboratory Quality and Workflow Monitoring
Clinical laboratories analyze blood, urine, tissue, and other bodily fluids to support disease diagnosis and treatment. Rising test volumes, workforce shortages, and increasingly complex diagnostics are... Read moreIndustry
view channel
Labcorp Partners With Grupo Fleury to Expand Clinical Trial Operations in Brazil
Multinational clinical trials require laboratory partners that combine global expertise with local operational capabilities. Brazil is an important clinical research destination, supported by its diverse... Read more







